Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Therapeutic options are limited for elderly patients with acute myeloid leukemia (AML). A phase Ib/II study was undertaken to evaluate the maximum-tolerated dose (MTD) and preliminary efficacy of the pan-histone deacetylase inhibitor panobinostat (LBH589) in combination with azacitidine in patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tan, P, Wei, A, Mithraprabhu, S, Cummings, N, Liu, H B, Perugini, M, Reed, K, Avery, S, Patil, S, Walker, P, Mollee, P, Grigg, A, D'Andrea, R, Dear, A, Spencer, A
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3913937/
https://ncbi.nlm.nih.gov/pubmed/24413064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2013.68
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky